Phibro Animal Health Corporation
Financials
Valuation Metrics
Phibro Animal Health Corporation's Market Cap is $1.57B. At end of 2025 it was $1.51B. Ranked #2142 of 3,118 in US market (top 69%), #831 of 1,474 on NASDAQ (top 56%), #154 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.57B | US#2,142/3,118 Sec#154/265 |
| Revenue | $1.52B | US#1,602/3,118 Sec#43/265 |
| Net Income | $100M | US#1,621/3,118 Sec#56/265 |
| Total Assets | $1.50B | US#2,253/3,118 Sec#67/265 |
| Net Assets | $385M | US#2,382/3,118 Sec#137/265 |
| Employees | 2,475 | US#1,567/3,118 Sec#37/265 |
| Value | ||
| P/E | 15.77x | US#835/3,118 Sec#27/265 |
| P/B | 4.08x | US#2,076/3,118 Sec#130/265 |
| PEG | 0.15x | US#255/3,118 Sec#10/265 |
| P/S | 1.04x | US#742/3,118 Sec#13/265 |
| EV/EBITDA | 9.73x | US#775/3,118 Sec#22/265 |
| FCF Yield | 0.63% | US#2,196/3,118 Sec#83/265 |
| Profitability | ||
| ROE | 25.87% | US#391/3,118 Sec#23/265 |
| ROA | 6.64% | US#839/3,118 Sec#47/265 |
| Op. Margin | 13.07% | US#1,334/3,118 Sec#55/265 |
| Revenue Growth | 17.12% | US#807/3,118 Sec#77/265 |
| Earnings Growth | 106.61% | US#280/3,118 Sec#12/265 |
| Financial Health | ||
| Debt Ratio | 289.45% | US#2,073/3,118 Sec#207/265 |
| Total Debt | $789M | US#1,646/3,118 Sec#49/265 |
| FCF | $10M | US#2,224/3,118 Sec#82/265 |
| Cash | $61M | US#2,486/3,118 Sec#214/265 |
| Current Ratio | 2.96x | US#793/3,118 Sec#192/265 |
| Net Debt/EBITDA | 3.08x | US#1,646/3,118 Sec#63/265 |
| Dividend | ||
| Div. Yield | 1.24% | US#1,202/3,118 Sec#20/265 |
| Div. Growth | 0.04% | US#1,253/3,118 Sec#23/265 |
| Performance | ||
| 1Y Return | -7.36% | US#2,028/3,118 Sec#159/265 |
| 1M Return | 4.11% | US#884/3,118 Sec#54/265 |
| From 52W High | -35.47% | US#2,166/3,118 Sec#147/265 |
| 1Y MDD | -52.13% | US#2,481/3,118 Sec#174/265 |
| Trading | ||
| Volume | 205,826 shares | US#2,730/3,118 Sec#253/265 |
| Trading Value | $8M | US#2,530/3,118 Sec#199/265 |
| Per Share | ||
| EPS | $2.46 | US#1,197/3,118 Sec#33/265 |
| BPS | $9.50 | US#1,876/3,118 Sec#73/265 |
Company Info
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.